KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Depreciation and Depletion (2018 - 2025)

Adaptive Biotechnologies' Depreciation and Depletion history spans 8 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 8.24% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $16.1 million, down 8.52%, while the annual FY2025 figure was $16.1 million, 8.52% down from the prior year.
  • Depreciation and Depletion for Q4 2025 was $3.7 million at Adaptive Biotechnologies, down from $4.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $5.3 million in Q3 2023 and bottomed at $2.3 million in Q1 2021.
  • The 5-year median for Depreciation and Depletion is $4.5 million (2021), against an average of $4.3 million.
  • The largest annual shift saw Depreciation and Depletion soared 126.09% in 2021 before it dropped 21.97% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $4.4 million in 2021, then increased by 9.41% to $4.8 million in 2022, then rose by 1.96% to $4.9 million in 2023, then dropped by 17.52% to $4.1 million in 2024, then dropped by 8.24% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Depreciation and Depletion are $3.7 million (Q4 2025), $4.0 million (Q3 2025), and $4.1 million (Q2 2025).